At their first dose of quadrivalent vaccine for human papillomavirus (HPV), more than 11% of young women aged 13 to 21 years who had never had sexual intercourse were already infected with 1 or more strains of HPV, a study has found.
At their first dose of quadrivalent vaccine for human papillomavirus (HPV), more than 11% of young women aged 13 to 21 years who had never had sexual intercourse were already infected with 1 or more strains of HPV, a study has found.
Researchers evaluated 259 young women recruited from an adolescent primary care clinic of whom 190 (73.4%) were sexually experienced (had had vaginal or anal intercourse). Nine (13%) of the 69 inexperienced study participants reported sexual contact (genital, skin-to-skin contact only). Eight of the sexually inexperienced participants (11.6%) were infected with HPV, as were 133 (70%) of the sexually experienced participants.
Of the sexually inexperienced participants, 2 (2.9%) were infected with HPV-16, 2 (2.9%) with HPV-68, none with HPV-18, and 3 (4.3%) with any vaccine-type HPV. Five patients had more than 1 HPV type (2 with 2 types and 3 with 3 types).
Inexperienced girls and women may have contracted HPV by hand-to-genital or genital skin-to-skin-only contact, the researchers speculate. They note that their study shows that sexually inexperienced girls and young women are vulnerable to HPV infection and it supports recommendations that 11- to 12-year-old girls be targeted for HPV immunization. Vaccination should not be delayed because a girl is not sexually active, they emphasize.
Read other articles in this issue of Special Delivery.
FDA adds boxed warning to fezolinetant for rare serious liver injury
Published: December 17th 2024 | Updated: December 17th 2024The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.
Read More